Publications by authors named "Masanari Yasuda"
Article Synopsis
- Nivolumab is the first-line treatment for platinum-resistant recurrent/metastatic head and neck cancer, but no predictive factors for treatment response have been identified.
- A study analyzed tumor infiltrating lymphocytes (TILs) in 28 patients to assess their impact on prognosis, finding that certain TILs (like FoxP3 and CD8 cells) did not correlate with survival.
- Key prognostic factors identified included objective response and PD-L1 status, with better outcomes for patients who had high stromal CD8TIL and PD-L1 positivity; these findings suggest potential markers for effectively predicting patient outcomes.
